Page last updated: 2024-11-12

roflumilast n-oxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

roflumilast N-oxide: an oral, once-daily phosphodiesterase 4 inhibitor; active metabolite of roflumilast [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9940999
CHEMBL ID4082392
SCHEMBL ID185643
SCHEMBL ID20756169
MeSH IDM0507392

Synonyms (34)

Synonym
roflumilast-d4 n-oxide
292135-78-5
FT-0674452
roflumilast n-oxide
benzamide, 3-(cyclopropylmethoxy)-n-(3,5-dichloro-1-oxido-4-pyridinyl)-4-(difluoromethoxy)-
f08mq6czcs ,
n-(3,5-dichloro-1-oxopyridin-4-yl)-4-difluoromethoxy-3-cyclopropylmethoxybenzamide
daxas n-oxide
roflumilast metabolite m07
byk22890
SCHEMBL185643
DTXSID80433059
3,5-dichloro-4-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzamido)pyridine 1-oxide
mfcd04112984
3,5-dichloro-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzamido]pyridin-1-ium-1-olate
AS-74398
3-(cyclopropylmethoxy)-n-(3,5-dichloro-1-oxido-4-pyridinyl)-4-(difluoromethoxy)-benzamide, 3-(cyclopropylmethoxy)-n-(3,5-dichloro-1-oxido-4-pyridinyl)-4-(difluoromethoxy)benzamide; n-(3,5-dichloro-1-oxopyridin-4-yl)-4-difluoromethoxy-3-cyclopropylmethoxyb
A1-04252
n-(3.5-dichloro-1-oxido-pyridin-4-yl)-4-difluoromethoxy-3-cyclopropylmethoxybenzamide
BCP28534
3,5-dichloro-4-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzamido)pyridine1-oxide
SCHEMBL20756169
3-(cyclopropylmethoxy)-n-(3,5-dichloro-1-hydroxypyridin-4-ylidene)-4-(difluoromethoxy)benzamide
CCG-277877
3, 5-dichloro-4-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzamido)pyridine 1-oxide
CHEMBL4082392
Q27277472
AKOS037515830
roflumilastn-oxide
A899569
khxxmsaruqulri-uhfffaoysa-n
3-(cyclopropylmethoxy)-n-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-4-(difluoromethoxy)benzamide
R0217
c17h14cl2f2n2o4

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"To model the pharmacokinetics of roflumilast and roflumilast N-oxide, evaluate the influence of potential covariates, use the total PDE4 inhibitory activity (tPDE4i) concept to estimate the combined inhibition of PDE4 by roflumilast and roflumilast N-oxide, and use individual estimates of tPDE4i to predict the occurrence of adverse events (AEs) in patients with moderate-to-severe COPD."( Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.
Diletti, E; Elmlinger, M; Facius, A; Hünnemeyer, A; Lahu, G; McCracken, N; Ruth, P; Zech, K, 2010
)
0.86

Pharmacokinetics

A minor decrease of exposure (area under the plasma concentration-time curve from time zero to infinity) and a small increase in elimination half-life (t(1/2) were observed in renally impaired patients compared with healthy subjects.

ExcerptReferenceRelevance
" Blood was sampled up to 54 hours for pharmacokinetic profiling of roflumilast and N-oxide."( Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects.
Bethke, TD; Hauns, B; Hauschke, D; Hermann, R; Herzog, R; Hünnemeyer, A; Zech, K, 2006
)
0.33
" The integrated exposure-weighted assessment of the observed pharmacokinetic changes of roflumilast and roflumilast N-oxide (tPDE4i) indicates modest average exposure increases to the sum of both compounds."( Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis.
de Mey, C; Hermann, R; Herzog, R; Knoerzer, D; Lahu, G; Nassr, N; Péterfai, E; Zech, K, 2007
)
0.81
"This nonrandomized, fixed-sequence, 3-period study investigated potential pharmacokinetic interactions between the leukotriene receptor antagonist montelukast, approved for the treatment of asthma, and roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor in clinical development for asthma and chronic obstructive pulmonary disease."( The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.
Böhmer, GM; Gleiter, CH; Hermann, R; Hünnemeyer, A; Lahu, G; Nassr, N; Templin, S; Wenger, M, 2009
)
0.35
"After co-administration of erythromycin and roflumilast, the mean AUC and Cmax of roflumilast increased by 70% and 40%, respectively."( Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide.
Elmlinger, M; Hermann, R; Herzog, R; Huennemeyer, A; Lahu, G; McCracken, N; Zech, K, 2009
)
0.58
" Pharmacokinetic profiles were obtained for days 1 to 6 and 12 to 19."( Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide.
Elmlinger, M; Herzog, R; Hinder, M; Huennemeyer, A; Lahu, G; Nassr, N; Ruth, P, 2011
)
0.59
" Posterior predictive checks and robustness analysis showed that the models adequately described the pharmacokinetic parameters and the covariate effects on disposition."( Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.
Diletti, E; Elmlinger, M; Facius, A; Hünnemeyer, A; Lahu, G; McCracken, N; Ruth, P; Zech, K, 2010
)
0.61
"A minor decrease of exposure (area under the plasma concentration-time curve from time zero to infinity (AUC(0-∞)), maximum plasma concentration (C(max))) and a small increase in elimination half-life (t(1/2)) of roflumilast (-1%; -6%; +19%, respectively) and roflumilast N-oxide (-%; ND; +30%, respectively) were observed in renally impaired patients compared with healthy subjects."( Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study.
Bethke, TD; Gleiter, CH; Hartmann, M; Hünnemeyer, A; Lahu, G, 2011
)
0.55
"The pharmacokinetic changes observed in patients with renal impairment are of small magnitude without clinical importance."( Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study.
Bethke, TD; Gleiter, CH; Hartmann, M; Hünnemeyer, A; Lahu, G, 2011
)
0.37
" The quantitation method was successfully applied for simultaneous estimation of IC87114, RFM and RFN in a pharmacokinetic drug-drug interaction study in Wistar rats."( Simultaneous quantitation of IC87114, roflumilast and its active metabolite roflumilast N-oxide in plasma by LC-MS/MS: application for a pharmacokinetic study.
Mukkanti, K; Thappali, SR; Vakkalanka, SK; Varanasi, KV; Veeraraghavan, S, 2012
)
0.61
" This method was successfully applied to a pharmacokinetic study in cynomolgus monkeys."( Simultaneous quantification and pharmacokinetic evaluation of roflumilast and its N-oxide in cynomolgus monkey plasma by LC-MS/MS method.
Fu, C; Qiu, F; Qu, H; Zhang, K, 2021
)
0.62

Compound-Compound Interactions

ExcerptReferenceRelevance
"4% to 10%) or in combination with a low concentration of LPS (0."( Roflumilast N-oxide prevents cytokine secretion induced by cigarette smoke combined with LPS through JAK/STAT and ERK1/2 inhibition in airway epithelial cells.
Boichot, E; Gleonnec, F; Lagente, V; Lanzetti, M; Porto, LC; Tenor, H; Valença, S; Victoni, T, 2014
)
1.85

Bioavailability

ExcerptReferenceRelevance
" For roflumilast, the covariates of sex, smoking and race influenced clearance; and food influenced the absorption rate constant and lag time."( Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.
Diletti, E; Elmlinger, M; Facius, A; Hünnemeyer, A; Lahu, G; McCracken, N; Ruth, P; Zech, K, 2010
)
0.61

Dosage Studied

ExcerptRelevanceReference
"To investigate the effects of steady-state dosing of fluvoxamine, an inhibitor of cytochrome P450 (CYP) 1A2 and CYP2C19, on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 (PDE4) inhibitor and its pharmacodynamically active metabolite roflumilast N-oxide."( Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.
Hermann, R; Herzog, R; Huennemeyer, A; Lahu, G; von Richter, O; Zech, K, 2007
)
0.76
" The current study involving 16 healthy adults investigated if the time-of-day of dosing of roflumilast, a novel phosphodiesterase-4 inhibitor, affects its pharmacokinetics."( Chronopharmacology of roflumilast: a comparative pharmacokinetic study of morning versus evening administration in healthy adults.
Bethke, TD; Huennemeyer, A; Lahu, G; Lemmer, B, 2010
)
0.36
" Future research will further elucidate the impact of roflumilast on COPD and beyond, while alternative dosing regimens may offer a means to ameliorate transient tolerability issues."( Pharmacokinetic evaluation of roflumilast.
Hünnemeyer, A; Lahu, G; Nassr, N, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1475425Fraction unbound in human plasma2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (42)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (21.43)29.6817
2010's30 (71.43)24.3611
2020's3 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.16 (24.57)
Research Supply Index3.95 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (21.43%)5.53%
Reviews1 (2.38%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other32 (76.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]